Prescient Therapeutics moves PTX-100 further in Phase 2a trial
Prescient Therapeutics says PTX-100 is being evaluated in a Phase 2a trial for Cutaneous T-Cell Lymphoma (CTCL).
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.